Periprosthetic Fractures

EAST PROVIDENCE, R.I., Feb. 6, 2024 /PRNewswire/ -- IlluminOss Medical, offering a unique, minimally invasive technology for fracture repair and stabilization in geriatric and compromised bone, announced it has reached the important benchmark of enrolling over 200 patients in its global device registry across 16 sites. IlluminOss will highlight the results of the patients in the registry at the upcoming American Academy of Orthopedic Surgeons meeting. Continue Reading IlluminOss Photodynamic Bone Stabilization System To further the evidence of the 1000+ patients' data in peer reviewed publications and conference proceedings, IlluminOss launched a clinical registry to demonstrate the real-world use of our device. The registry is designed to collect safety and performance data on the IlluminOss Device when used to provide stabilization and alignment for the treatment of fractures in compromised bone. The registry aims to show real world outcomes for the system. Standard of care follow up visit data is collected at 75 days, 6 months, and 1 year from the initial procedure. Over half of the patients enrolled have already reached their first follow up visit. About the IlluminOss Photodynamic Bone Stabilization System IlluminOss technology involves expanding a balloon-like implant inside a fractured bone by infusing the implant with a light-curing liquid. Blue light is then transmitted to the implant via an optical fiber to convert the liquid into a polymer, creating a strong core within the bone. This stabilizes the fracture and allows for a fast return to daily activities. Some patients are able to regain use of their injured limb the day of surgery. If additional fracture fixation is necessary, the strength supplied by the IlluminOss implant allows surgical plates and screws to be securely fastened into the bone. Dr. Jason Halvorson, Orthopedic trauma surgeon and study investigator from Raleigh, NC says "I started using this only for periprosthetic fractures and have now used it when I need to increase stability and the construct stiffness of the fracture. I don't have to worry about screwing into the bone. The IlluminOss system augments poor bone, allowing for an increase in bone strength. Having the IlluminOss implant gives my patients the opportunity for early mobilization and weight bearing." About IlluminOss Medical, Inc. Headquartered in East Providence, RI, IlluminOss is a privately held, commercial-stage medical device company. The IlluminOss system is CE-marked and FDA-cleared for a variety of anatomical sites, with further indications pending. For additional information, including a complete list of indications, contraindications, warnings, precautions and risks, visit . For any press questions, please contact Lisa Holt, at [email protected] . SOURCE IlluminOss Medical

Session to highlight how surgeons are using CurvaFix IM Implant for complex pelvic morphology, periprosthetic fracture, and Fragility Fractures of the Pelvis BELLEVUE, Wash.--(BUSINESS WIRE)-- CurvaFix, Inc., a developer of medical devices that delivers stable fixation for curved anatomy and poor bone, has announced that it will host an Industry Session at the 39th annual meeting of the Orthopaedic Trauma Association (OTA), Oct. 18-21 in Seattle. Participants will learn how surgeons successfully utilize the CurvaFix® IM Implant, the only intramedullary implant that follows and fills the natural curvature of the pelvis, to treat patients with challenging pelvic fractures. This press release features multimedia. View the full release here: CurvaFix is hosting an Industry Session at the 39th annual meeting of the Orthopaedic Trauma Association (OTA), Oct. 18-21 in Seattle, highlighting how surgeons are using the CurvaFix Implant for complex pelvic morphology, periprosthetic fracture, and fragility fractures of the pelvis. (Graphic: Business Wire) CurvaFix also announced that a poster by Amir Matityahu, M.D., and additional authors outlining the results from a multicenter study evaluating the CurvaFix Implant will be presented at the annual meeting. The research, performed at seven centers in the U.S. and Canada, found that the CurvaFix Implant was safe and provided successful fixation of pelvic and acetabular fractures. The company will also showcase the CurvaFix procedure in booth #522 and provide updates on recent cases. The Industry Session will occur on Thursday, Oct. 19, 7:00 am – 7:50 am (PT) in room 3B at the Seattle Convention Center, Arch Bldg. The educational session will include compelling case reviews, an overview of the CurvaFix technology, and panel discussions featuring Brett Crist, M.D., University of Missouri, Samir Mehta, M.D., Matthew Gardner, M.D., Springfield Clinic, John Michael Yingling, D.O., OU Health, Oklahoma, Prof. Dr. Pol M. Rommens, retired, University Medical Center of the Johannes Gutenberg-University of Mainz, Germany, and Langdon A. Hartsock, M.D., Medical University of South Carolina. “With the aging population, osteoporosis is on the rise, making it imperative that surgeons have access to advanced technology that enables them to repair pelvic fractures that may cause significant pain and significantly limit patient mobilization,” said Dr. Crist. “The truly novel technology is minimally invasive, features outstanding intro-operative maneuverability, and has the potential for significant pain relief and faster mobility.” Industry Session participants will hear how surgeons are utilizing the CurvaFix IM Implant to treat complicated pelvic morphology, periprosthetic fractures, and Fragility Fractures of the Pelvis (FFP). This event will include an update in early usage data, recent case presentations, and an evidence update on FFP. “The CurvaFix Implant allows me to select the optimal surgical entry point and steer within the bone according to the patient’s anatomy,” said Dr. Mehta. “The result is durable, curved fixation—all in about 20 minutes. I see this as an optimal alternative solution for certain pelvic and acetabular fractures, especially with complex or atypical anatomy.” “We’re thrilled to be hosting an Industry Session and presenting a poster at the OTA Annual Meeting, as we showcase the CurvaFix Implant, the most sophisticated technology to date for pelvic fracture repair,” said Mark Foster, chief executive officer of CurvaFix. “Numerous case studies have shown that the CurvaFix Implant is able to overcome the limitations of existing implants used for pelvic fracture fixation in both high-impact trauma and fragility fracture patients. We are focused on Restoring Mobility and Renewing Lives.” About CurvaFix, Inc. CurvaFix, Inc. is a privately held medical device company headquartered in Bellevue, Wash. CurvaFix is developing implantable products to improve fracture repair in curved bones. The company is focusing on Fragility Fractures of the Pelvis and high-impact pelvic fractures. The CurvaFix IM Implant has received 510(k) clearance from the U.S. Food & Drug Administration (FDA).

LAS VEGAS, March 8, 2023 /PRNewswire/ -- A study by Hospital for Special Surgery (HSS) and other centers found that total hip replacement performed with a cementless prosthesis for a femoral neck fracture led to a higher rate of a second fracture and subsequent revision surgery. The research was presented today at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas. The results were also published online in The Journal of Arthroplasty in October 2022. Treatments for a femoral neck fracture range from nonoperative management to total hip replacement. When hip replacement is the best treatment option, it can be performed with or without bone cement to secure the prosthesis. "Femoral neck fractures are very common in the elderly and are a major cause of morbidity and mortality in this population," explained Alexander McLawhorn, MD, a hip and knee orthopedic surgeon at HSS and study author. "Several national registry studies have demonstrated a lower risk of overall revision surgery, and specifically revision for periprosthetic fracture, with cemented femoral fixation. Despite this overwhelming data, many patients in the United States receive cementless fixation, including patients who have sustained femoral neck fractures." "To our knowledge, this was the first non-registry study comparing outcomes of cemented versus cementless total hip replacement for acute femoral neck fractures examining the influence of various patient factors, including bone quality," explained Michael Kheir, MD, who presented the study at the AAOS meeting and played a leading role in the research during his fellowship at HSS. "The primary purpose was to compare complication rates between both groups, including periprosthetic fractures, aseptic revision, dislocation and mortality rates." Dr. Kheir is currently an orthopedic surgeon specializing in hip and knee replacement at the University of Michigan. The retrospective study analyzed 709 total hip replacement cases (199 cemented, 510 cementless) for femoral neck fractures from 2006 to 2020 at three large academic institutions: Hospital for Special Surgery, Indiana University Health and University Hospitals Cleveland Medical Center. Patient demographics, perioperative characteristics and x-rays were reviewed. The Dorr classification system, widely used to evaluate femoral bone quality, categorized patients with Dorr type A, B or C, with type C indicating the weakest bone. The average age of study participants was 71 years; 66.9% of patients were women. The prevalence of Dorr type bone was 21.1% type A; 66.3% type B; and 12.6% type C. Patients receiving cemented implants were older, had a lower BMI, were more often women and were more likely to have a pre-existing diagnosis of osteoporosis and Dorr C bone type. Cementless implant stems had a higher all-cause aseptic femoral revision rate (5.1 versus 0.5%,) and periprosthetic femoral fracture rate (4.3 versus 0%). Bone classification played a major role: Each successive Dorr grade had a higher fracture rate with cementless implants (Dorr A =2.3%; Dorr B = 3.7%; Dorr C = 15.9%). There was no difference in rates of dislocation, revision due to infection or mortality rate between groups. The study found an equal distribution of male and female patients who sustained a fracture. "While femoral fractures occurred in patients with all types of bone quality, Dorr C bone was particularly prone, with an alarmingly high fracture rate when using cementless stems," Dr. Kheir noted. "All of the fractures requiring a revision surgery occurred in cementless cases, suggesting that cemented stems may minimize this complication, regardless of patient sex or Dorr classification." Authors: Alexander McLawhorn, MD, MBA; Emile-Victor Kuyl, BS, (HSS); George Ochenjele, MD, FAAOS, (UH Cleveland Medical Center); Jacob Speybroeck, MD; Julian Dilley, MD, (Indiana University Health); Michael M. Kheir, MD, (University of Michigan); R M. Meneghini, MD, FAAOS, (Indiana University Health Phys) About HSS HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 13th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2022-2023), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report "Best Children's Hospitals" list (2022-2023). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a third consecutive year (2023). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 145 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. . SOURCE Hospital for Special Surgery